Pemigatinib
- Generic Name
- Pemigatinib
- Brand Names
- Pemazyre
- Drug Type
- Small Molecule
- Chemical Formula
- C24H27F2N5O4
- CAS Number
- 1513857-77-6
- Unique Ingredient Identifier
- Y6BX7BL23K
- Background
Pemigatinib is a small molecule kinase inhibitor with antitumour activity. It works by inhibiting fibroblast growth factor receptors (FGFRs), which are receptor tyrosine kinases that activate signalling pathways in tumour cells. FGFRs gained attention as potential therapeutic targets in selected cancers, as FGFR gene alterations were observed in a wide varie...
- Indication
Pemigatinib is indicated for the treatment of unresectable locally advanced or metastatic cholangiocarcinoma in previously-treated adult patients with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test.
...
- Associated Conditions
- Refractory Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement, Relapsed Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement, Unresectable, locally advanced Cholangiocarcinomas, Unresectable, metastatic Cholangiocarcinomas
- Associated Therapies
- -
A Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk Tumors
- Conditions
- Interventions
- First Posted Date
- 2019-04-16
- Last Posted Date
- 2024-06-18
- Target Recruit Count
- 43
- Registration Number
- NCT03914794
- Locations
- 🇺🇸
Associated Medical Professionals Urology, Syracuse, New York, United States
🇺🇸Midlantic Urology, Bala-Cynwyd, Pennsylvania, United States
🇺🇸Sibley Memorial Hospital, Washington, District of Columbia, United States
Expanded Access of Pemigatinib to Treat a Single Patient With Metastatic Pancreatic Cancer
- First Posted Date
- 2019-04-08
- Last Posted Date
- 2022-04-19
- Lead Sponsor
- Incyte Corporation
- Registration Number
- NCT03906357
Efficacy and Safety of Pemigatinib in Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)
- First Posted Date
- 2019-01-30
- Last Posted Date
- 2023-03-20
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 111
- Registration Number
- NCT03822117
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Cancer Treatment Centers of America, Zion, Illinois, United States
🇺🇸Carle Cancer Center, Urbana, Illinois, United States
A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2018-09-04
- Last Posted Date
- 2024-07-26
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 167
- Registration Number
- NCT03656536
- Locations
- 🇺🇸
Parkview Research Center, Fort Wayne, Indiana, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site
- Conditions
- Interventions
- Drug: AlectinibDrug: VismodegibDrug: IpatasertibDrug: CarboplatinDrug: OlaparibDrug: ErlotinibDrug: CisplatinDrug: BevacizumabDrug: GemcitabineDrug: VemurafenibDrug: CobimetinibDrug: Trastuzumab Subcutaneous (SC)Drug: PertuzumabDrug: AtezolizumabDrug: PaclitaxelDrug: EntrectinibDrug: IvosidenibDrug: Pemigatinib
- First Posted Date
- 2018-04-13
- Last Posted Date
- 2024-06-14
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 528
- Registration Number
- NCT03498521
- Locations
- 🇦🇺
Northern Cancer Institute, St Leonards, New South Wales, Australia
🇦🇺Blacktown Hospital, Blacktown, New South Wales, Australia
🇫🇮Helsinki University Central Hospital; Dept of Oncology, Helsinki, Finland
A Safety and Tolerability Study of Pemigatinib in Japanese Subjects With Advanced Malignancies - (FIGHT-102)
- First Posted Date
- 2017-08-01
- Last Posted Date
- 2020-05-29
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 44
- Registration Number
- NCT03235570
- Locations
- 🇯🇵
Chiba Cancer Center, Chiba, Japan
🇯🇵Osaka International Cancer Institute, Osaka, Japan
🇯🇵Saitama Cancer Center, Saitama, Japan
A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203)
- First Posted Date
- 2017-01-05
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 47
- Registration Number
- NCT03011372
- Locations
- 🇺🇸
Stanford Cancer Institute, Stanford, California, United States
🇫🇷Chu de Nice - Hospital L Archet, Nice Cedex 3, France
🇩🇪Universitatsklinikum Jena, Jena, Germany
The Drug Rediscovery Protocol (DRUP Trial)
- Conditions
- Interventions
- Drug: PanitumumabDrug: OlaparibDrug: CrizotinibDrug: ErlotinibDrug: AlectinibDrug: Ipilimumab and nivolumabDrug: SunitinibDrug: Trastuzumab and Pertuzumab (combination treatment)Drug: Vemurafenib and Cobimetinib (combination treatment)Drug: NivolumabDrug: Dabrafenib and trametinibDrug: SelpercatinibDrug: TepotinibDrug: AbemaciclibDrug: ErdafitinibDrug: Atezolizumab and BevacizumabDrug: DacomitinibDrug: DabrafenibDrug: NilotinibDrug: TrametinibDrug: VismodegibDrug: RegorafenibDrug: AfatinibDrug: RibociclibDrug: LenvatinibDrug: PembrolizumabDrug: DurvalumabDrug: RucaparibDrug: AxitinibDrug: PalbociclibDrug: CabozantinibDrug: EntrectinibDrug: TalazoparibDrug: LorlatinibDrug: AlpelisibDrug: NiraparibDrug: Pemigatinib
- First Posted Date
- 2016-10-05
- Last Posted Date
- 2024-01-24
- Lead Sponsor
- The Netherlands Cancer Institute
- Target Recruit Count
- 1550
- Registration Number
- NCT02925234
- Locations
- 🇳🇱
Meander medisch centrum, Amersfoort, Netherlands
🇳🇱Netherlands Cancer Institute, Amsterdam, Netherlands
🇳🇱Amsterdam UMC, locatie AMC, Amsterdam, Netherlands
Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy - (FIGHT-202)
- First Posted Date
- 2016-10-05
- Last Posted Date
- 2023-02-23
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 147
- Registration Number
- NCT02924376
A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Urothelial Carcinoma - (FIGHT-201)
- First Posted Date
- 2016-08-19
- Last Posted Date
- 2023-03-24
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 263
- Registration Number
- NCT02872714
- Locations
- 🇩🇪
Klinikum Dresden Standort Dresden-Friedrichstadt, Dresden, Germany
🇩🇪Universitaetsklinikum Carl Gustav Carus TU Dresden, Dresden, Germany
🇩🇪Universitaetsklinikum Hamburg-Eppendorf, Hamburg, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.